The combined PTPRZ1 and PTN expression is more significant to predict the outcomes of GBM patients (Supplementary Fig. 4i,j), suggesting that PTPRZ1 and PTN may serve as a prognostic biomarker set for GBM patients. This evidence concerns the gene PTN and glioblastoma.